Emergent BioSolutions, Inc. (EBS)
8.24
+0.29
(+3.65%)
USD |
NYSE |
Jun 10, 16:00
8.245
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Enterprise Value : 885.31M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 885.31M |
| June 08, 2026 | 887.90M |
| June 05, 2026 | 891.53M |
| June 04, 2026 | 910.69M |
| June 03, 2026 | 884.27M |
| June 02, 2026 | 898.78M |
| June 01, 2026 | 913.28M |
| May 29, 2026 | 945.92M |
| May 28, 2026 | 949.02M |
| May 27, 2026 | 937.87M |
| May 26, 2026 | 944.57M |
| May 22, 2026 | 909.49M |
| May 21, 2026 | 905.36M |
| May 20, 2026 | 894.01M |
| May 19, 2026 | 889.37M |
| May 18, 2026 | 892.98M |
| May 15, 2026 | 883.17M |
| May 14, 2026 | 897.11M |
| May 13, 2026 | 903.30M |
| May 12, 2026 | 912.07M |
| May 11, 2026 | 935.29M |
| May 08, 2026 | 963.66M |
| May 07, 2026 | 944.57M |
| May 06, 2026 | 943.03M |
| May 05, 2026 | 940.45M |
| Date | Value |
|---|---|
| May 04, 2026 | 914.13M |
| May 01, 2026 | 910.52M |
| April 30, 2026 | 898.14M |
| April 29, 2026 | 885.75M |
| April 28, 2026 | 898.14M |
| April 27, 2026 | 887.82M |
| April 24, 2026 | 887.82M |
| April 23, 2026 | 890.91M |
| April 22, 2026 | 902.92M |
| April 21, 2026 | 887.90M |
| April 20, 2026 | 906.03M |
| April 17, 2026 | 929.86M |
| April 16, 2026 | 920.02M |
| April 15, 2026 | 922.09M |
| April 14, 2026 | 922.09M |
| April 13, 2026 | 900.33M |
| April 10, 2026 | 885.83M |
| April 09, 2026 | 911.21M |
| April 08, 2026 | 908.10M |
| April 07, 2026 | 880.13M |
| April 06, 2026 | 893.08M |
| April 02, 2026 | 899.81M |
| April 01, 2026 | 907.58M |
| March 31, 2026 | 903.44M |
| March 30, 2026 | 790.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.936B |
| Alnylam Pharmaceuticals, Inc. | 39.69B |
| Savara, Inc. | 837.60M |
| Vericel Corp. | 1.840B |
| Biogen, Inc. | 31.67B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 6.80M |
| Revenue (Quarterly) | 156.10M |
| Total Expenses (Quarterly) | 149.30M |
| EPS Diluted (Quarterly) | 0.0743 |
| Gross Profit Margin (Quarterly) | 43.31% |
| Profit Margin (Quarterly) | 4.36% |
| Earnings Yield | -3.43% |
| Operating Earnings Yield | 15.74% |
| Normalized Earnings Yield | -0.8349 |